STOCK TITAN
  1. Home
  2. Sec-filings
  3. CRDF
  4. [Form 4] Cardiff Oncology, Inc. Insider Trading Activity

Cardiff Oncology (CRDF) director receives grant of 40,565 stock options at $1.59

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Cardiff Oncology director receives stock option grant

Cardiff Oncology, Inc. director Rodney S. Markin was granted stock options covering 40,565 shares of common stock. These options have a conversion price of $1.59 per share and relate to an equal number of underlying common shares.

Following this award, Markin holds a total of 263,430 derivative securities, reflecting his updated stock option position with the company.

Positive

  • None.

Negative

  • None.
Insider Markin Rodney S
Role null
Type Security Shares Price Value
Grant/Award Stock Options 40,565 $0.00 --
Holdings After Transaction: Stock Options — 263,430 shares (Direct, null)
Footnotes (1)
Options granted 40,565 options Stock option award to director Rodney S. Markin
Exercise price $1.59 per share Conversion or exercise price of granted options
Underlying shares 40,565 shares Common stock underlying the stock options
Total derivatives after grant 263,430 securities Total derivative securities held after transaction
Expiration date June 11, 2036 Stock options expiration date
Stock Options financial
"security_title: "Stock Options" related to Cardiff Oncology common stock"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
derivative securities financial
"total_shares_following_transaction shows 263,430 derivative securities held"
Financial contracts whose value is tied to the price or performance of another asset, such as a stock, bond, commodity, index, or currency; examples include options, futures and swaps. They matter to investors because they let you protect against price swings, bet on future moves or gain larger exposure with less upfront cash—like using a lever or insurance policy on an investment—so they can amplify gains and losses and help manage portfolio risk.
exercise price financial
"conversion_or_exercise_price field lists an exercise price of 1.5900"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
underlying security financial
"underlying_security_title is identified as Common Stock"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Markin Rodney S
(Last)(First)(Middle)
C/O CARDIFF ONCOLOGY, INC.
11055 FLINTKOTE AVENUE
(Street)
SAN DIEGO CALIFORNIA 92121
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Cardiff Oncology, Inc. [ CRDF ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/11/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Options$1.5906/11/2026A40,56506/11/202706/11/2036Common Stock40,565$0263,430D
Explanation of Responses:
/s/ Rodney S. Markin06/15/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Cardiff Oncology (CRDF) director Rodney S. Markin report on this Form 4?

Rodney S. Markin reported receiving stock options for 40,565 shares of Cardiff Oncology common stock. These options are a compensation-related grant, not an open-market stock purchase or sale.

How many Cardiff Oncology (CRDF) options were granted to Rodney S. Markin?

Rodney S. Markin was granted stock options covering 40,565 shares of Cardiff Oncology common stock. The options give him the right to acquire these shares at a set exercise price.

What is the exercise price of Rodney S. Markin’s new Cardiff Oncology (CRDF) options?

The newly granted stock options have an exercise price of $1.59 per share. This means Markin can acquire Cardiff Oncology common shares at $1.59 when the options become exercisable.

How many Cardiff Oncology (CRDF) derivative securities does Rodney S. Markin hold after this transaction?

After the stock option grant, Rodney S. Markin holds 263,430 derivative securities. This figure reflects his updated total stock option position reported in the Form 4 filing.

Is Rodney S. Markin’s Cardiff Oncology (CRDF) Form 4 a stock sale or purchase?

The Form 4 reflects a grant of stock options, not a market sale or purchase. It represents a compensation-related award giving Markin the right to acquire shares at a fixed exercise price.